- Home
- ICG vs CRVS Comparison
ICG vs CRVS Comparison
Compare ICG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICG
- CRVS
- Stock Information
- Founded
- ICG 2017
- CRVS 2014
- Country
- ICG China
- CRVS United States
- Employees
- ICG N/A
- CRVS N/A
- Industry
- ICG Semiconductors
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ICG Technology
- CRVS Health Care
- Exchange
- ICG Nasdaq
- CRVS Nasdaq
- Market Cap
- ICG 230.3M
- CRVS 257.0M
- IPO Year
- ICG 2023
- CRVS 2016
- Fundamental
- Price
- ICG $2.55
- CRVS $3.13
- Analyst Decision
- ICG Strong Buy
- CRVS Strong Buy
- Analyst Count
- ICG 1
- CRVS 5
- Target Price
- ICG $11.00
- CRVS $12.63
- AVG Volume (30 Days)
- ICG 24.2K
- CRVS 657.7K
- Earning Date
- ICG 05-15-2025
- CRVS 03-25-2025
- Dividend Yield
- ICG N/A
- CRVS N/A
- EPS Growth
- ICG N/A
- CRVS N/A
- EPS
- ICG 0.12
- CRVS N/A
- Revenue
- ICG $38,602,978.00
- CRVS N/A
- Revenue This Year
- ICG N/A
- CRVS N/A
- Revenue Next Year
- ICG N/A
- CRVS N/A
- P/E Ratio
- ICG $23.03
- CRVS N/A
- Revenue Growth
- ICG 242.68
- CRVS N/A
- 52 Week Low
- ICG $2.24
- CRVS $1.30
- 52 Week High
- ICG $12.04
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ICG 33.18
- CRVS 27.58
- Support Level
- ICG $2.66
- CRVS $3.20
- Resistance Level
- ICG $3.08
- CRVS $3.45
- Average True Range (ATR)
- ICG 0.27
- CRVS 0.37
- MACD
- ICG -0.11
- CRVS -0.11
- Stochastic Oscillator
- ICG 6.76
- CRVS 3.55
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).